Leerink Swann Raises Price Target on Regeneron (REGN) to $182
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $898.97 -0.25%
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 14 | New: 16
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 14 | New: 16
Join SI Premium – FREE
Leerink Swann reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $182.00 (from $150.00).
MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that suggests to that Eylea can continue to meet or beat street revenue estimates this year and next.
"Surveyed physicians still project a big step up in Eylea wet AMD market penetration over the next year. Treatment experienced patient penetration is expected to rise from 20.5% currently to 29% in one year and 33% in two years. Treatment naïve patient penetration is expected to rise from 17.5% currently to 26.6% in one year and 31.8% in two years,” said analyst Joseph P. Schwartz.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $158.24 yesterday.
MEDACorp conducted a survey of 50 U.S.ophthalmologists and based on the results analyst at Leerink Swan created a revenue model that suggests to that Eylea can continue to meet or beat street revenue estimates this year and next.
"Surveyed physicians still project a big step up in Eylea wet AMD market penetration over the next year. Treatment experienced patient penetration is expected to rise from 20.5% currently to 29% in one year and 33% in two years. Treatment naïve patient penetration is expected to rise from 17.5% currently to 26.6% in one year and 31.8% in two years,” said analyst Joseph P. Schwartz.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $158.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
- Deckers Outdoor (DECK) PT Raised to $1,005 at TD Cowen
- Chevron (CVX) PT Raised to $204 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
